Kalvista Pharmaceuticals (NASDAQ:KALV) Lowered to “D+” at TheStreet

TheStreet cut shares of Kalvista Pharmaceuticals (NASDAQ:KALV) from a c- rating to a d+ rating in a report issued on Thursday morning, TheStreetRatingsTable reports.

Several other analysts have also recently weighed in on KALV. Zacks Investment Research cut ExlService from a hold rating to a sell rating in a report on Wednesday, July 10th. BidaskClub cut Vertex Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, July 9th. Needham & Company LLC boosted their price target on Zuora from $27.00 to $30.00 and gave the stock a strong-buy rating in a report on Wednesday, March 20th. ValuEngine cut Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. Finally, Roth Capital restated a buy rating on shares of Kalvista Pharmaceuticals in a report on Tuesday, May 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $29.40.

NASDAQ:KALV opened at $17.31 on Thursday. The company has a market capitalization of $298.55 million, a PE ratio of -11.31 and a beta of 2.12. The business’s 50-day moving average price is $20.59. Kalvista Pharmaceuticals has a 1-year low of $7.95 and a 1-year high of $34.92.

In related news, CFO Benjamin L. Palleiko sold 1,073 shares of the company’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $25.51, for a total value of $27,372.23. Following the sale, the chief financial officer now directly owns 33,573 shares in the company, valued at $856,447.23. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Edward P. Feener sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $24.92, for a total value of $99,680.00. Following the completion of the sale, the insider now owns 100,950 shares in the company, valued at $2,515,674. The disclosure for this sale can be found here. Insiders sold 15,501 shares of company stock worth $397,553 over the last quarter. 38.40% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in the stock. FMR LLC bought a new stake in shares of Kalvista Pharmaceuticals in the 1st quarter worth approximately $21,036,000. Marshall Wace North America L.P. bought a new stake in shares of Kalvista Pharmaceuticals during the first quarter valued at approximately $175,000. Marshall Wace LLP bought a new stake in shares of Kalvista Pharmaceuticals during the first quarter valued at approximately $843,000. Laurion Capital Management LP boosted its position in shares of Kalvista Pharmaceuticals by 94.9% during the first quarter. Laurion Capital Management LP now owns 58,871 shares of the specialty pharmaceutical company’s stock valued at $1,685,000 after purchasing an additional 28,670 shares in the last quarter. Finally, Bank of Montreal Can boosted its position in shares of Kalvista Pharmaceuticals by 28.5% during the first quarter. Bank of Montreal Can now owns 5,824 shares of the specialty pharmaceutical company’s stock valued at $166,000 after purchasing an additional 1,292 shares in the last quarter. Institutional investors and hedge funds own 80.64% of the company’s stock.

Kalvista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Featured Story: What are the risks of holding treasury bonds?

Analyst Recommendations for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.